Table 3 Anticancer activity of ED@AuNPs.
Concentration µg/mL | Sample | Absorbance (1) | Absorbance (2) | Absorbance (3) | Viability (%) (1) | Viability (%) (2) | Viability (%) (3) | Average Viability (%) | S.D |
|---|---|---|---|---|---|---|---|---|---|
40 | Control | 0.312 | 0.322 | 0.317 | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 |
10 | AuNPs | 0.210 | 0.215 | 0.212 | 70.45 | 72.10 | 71.28 | 71.28 | 0.83 |
20 | AuNPs | 0.185 | 0.190 | 0.188 | 65.32 | 67.45 | 66.14 | 66.30 | 1.07 |
50 | AuNPs | 0.170 | 0.175 | 0.172 | 60.25 | 62.30 | 61.40 | 61.32 | 1.03 |
100 | AuNPs | 0.160 | 0.165 | 0.162 | 55.14 | 57.25 | 56.20 | 56.20 | 1.06 |
150 | AuNPs | 0.150 | 0.155 | 0.152 | 50.12 | 52.30 | 51.20 | 51.21 | 1.08 |
200 | AuNPs | 0.143 | 0.159 | 0.151 | 45.83 | 49.38 | 47.63 | 47.62 | 1.77 |
